Patents by Inventor Ronald J. Berenson

Ronald J. Berenson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20040241162
    Abstract: The present invention relates generally to methods for activating and expanding cells, and more particularly, to a novel method to activate and/or stimulate cells that maximizes the expansion of such cells to achieve dramatically high densities. In the various embodiments, cells are activated and expanded to very high densities in a short period of time. In certain embodiments, cells are activated and expanded to very high numbers of cells in a short period of time. Compositions of cells activated and expanded by the methods herein are further provided.
    Type: Application
    Filed: January 20, 2004
    Publication date: December 2, 2004
    Applicant: XCYTE Therapies, Inc.
    Inventors: Ronald J. Berenson, Che Law, Mark Bonyhadi, Narinder Saund, Stewart Craig, Alan Hardwick, Dale Kalamasz, David McMillen, Harjinder Singh Chana
  • Publication number: 20040005298
    Abstract: The present invention relates generally to methods for stimulating, activating, and maintaining or increasing the polyclonality of expressed TCRs in a population of T cells. In the various embodiments, cells are stimulated with a surface, wherein the surface has attached thereto one or more agents that ligate a cell surface moiety of at least a portion of the T cells and stimulates at least a portion of the T cells, yielding enhanced proliferation, cell signal transduction, and/or cell surface moiety aggregation. In certain aspects methods for stimulating a population of cells such as T-cells, by cell surface moiety ligation are provided by contacting the population of cells with a surface, that has attached thereto one or more agents that ligate a cell surface moiety thereby inducing cell stimulation, cell surface moiety aggregation, and/or receptor signaling enhancement.
    Type: Application
    Filed: February 7, 2003
    Publication date: January 8, 2004
    Applicant: XCYTE Therapies, Inc.
    Inventors: Mark Bonyhadi, Ronald J. Berenson
  • Patent number: 5635387
    Abstract: Methods for increasing the number of human hematopoietic precursor cells in vitro are provided. The methods generally comprise (a) separating human hematopoietic precursor cells from mature hematopoietic cells present in a blood product; (b) inoculating the separated precursor cells into a culture vessel containing a culture medium comprising a nutritive medium and a source of growth factors at a density of between 1.times.10.sup.3 cells/ml and 4.times.10.sup.6 cells/ml; and (c) culturing the cells under conditions and for a time sufficient to increase the number of precursor cells relative to the number of such cells present in the blood product. The culture medium may also include a suitable amount of microcarrier beads. Suitable blood products include bone marrow, umbilical cord blood, and peripheral blood. A device for carrying out such methods is also provided.
    Type: Grant
    Filed: April 3, 1995
    Date of Patent: June 3, 1997
    Assignee: CellPro, Inc.
    Inventors: Rui G. Fei, Shelly Heimfeld, Billy W. Minshall, Ronald J. Berenson
  • Patent number: 5378624
    Abstract: A method is provided for removing a second ligand from a particle surface without substantially affecting the particle surface, comprising the step of exposing the particle to a first ligand immobilized onto a support, wherein the particle is exposed under conditions and for a residence time sufficient to allow the second ligand to desorb from the particle surface, and wherein the first ligand has an affinity for the second ligand that is at least two orders of magnitude greater than the affinity of the second ligand for the particle surface, such that the second ligand is removed from the particle surface without substantially affecting the particle surface.
    Type: Grant
    Filed: April 23, 1990
    Date of Patent: January 3, 1995
    Assignee: CellPro, Incorporated
    Inventors: Ronald J. Berenson, Dale R. Peterson
  • Patent number: 5262334
    Abstract: The selectivity of immunoselection systems employing insolubilized avidin and biotinylated specific antibody is amplified, and nonspecific recovery is improved, by employing an indirect sandwich technique using a biotin-conjugated antispecies immunoglobulin that is directed to one or more nonbiotinylated specific antibodies in conjunction with insolubilized avidin. Specific cell populations can be removed and recovered from bone marrow, providing excellent recovery of bone marrow and preservation of hematopoietic stem cells for transplantation. Mixed populations of T cells or of tumor cells can be conveniently and simultaneously removed with minimal manipulation of the marrow cells. An improved positive immunoselection method provides viable and functional recovered cells, e.g., hematopoietic stem cells or activated killer cells, that can be clinically employed.
    Type: Grant
    Filed: October 3, 1991
    Date of Patent: November 16, 1993
    Assignee: Fred Hutchinson Cancer Research Center
    Inventors: Ronald J. Berenson, William I. Bensinger
  • Patent number: 5225353
    Abstract: The selectivity of immunoselection systems employing insolubilized avidin and biotinylated specific antibody is amplified, and nonspecific recovery is improved, by employing an indirect sandwich technique using a biotin-conjugated antispecies immunoglobulin that is directed to one or more nonbiotinylated specific antibodies in conjunction with insolubilized avidin. Specific cell populations can be removed and recovered from bone marrow, providing excellent recovery of bone marrow and preservation of hematopoietic stem cells for transplantation. Mixed populations of T cells or of tumor cells can be conveniently and simultaneously removed with minimal manipulation of the marrow cells. An improved positive immunoselection method provides viable and functional recovered cells, e.g., hematopoietic stem cells or activated killer cells, that can be clinically employed.
    Type: Grant
    Filed: October 3, 1991
    Date of Patent: July 6, 1993
    Assignee: Fred Hutchinson Cancer Research Center
    Inventors: Ronald J. Berenson, William I. Bensinger
  • Patent number: 5215927
    Abstract: The selectivity of immunoselection systems employing insolubilized avidin and biotinylated specific antibody is amplified, and nonspecific recovery is improved, by employing an indirect sandwich technique using a biotin-conjugated antispecies immunoglobulin that is directed to one or more nonbiotinylated specific antibodies in conjunction with insolubilized avidin. Specific cell populations can be removed and recovered from bone marrow, providing excellent recovery of bone marrow and preservation of hematopoietic stem cells for transplantation. Mixed populations of T cells or of tumor cells can be conveniently and simultaneously removed with minimal manipulation of the marrow cells. An improved positive immunoselection method provides viable and functional recovered cells, e.g., hematopoietic stem cells or activated killer cells, that can be clinically employed.
    Type: Grant
    Filed: August 2, 1991
    Date of Patent: June 1, 1993
    Assignee: Fred Hutchinson Cancer Research Center
    Inventors: Ronald J. Berenson, William I. Bensinger